Philips, USFDA in talks post new ventilator findings

Published On 2021-11-15 10:11 GMT | Update On 2021-11-22 15:46 GMT

Amsterdam: Philips, the medical equipment maker that is recalling ventilators due to use of parts containing a potentially hazardous foam, said on Sunday it is in dicussions with U.S. regulators after a new inspection of one of the company's facilities.

Philips in September estimated it will replace up to 4 million vetilators and respiratory devices because of a polyurethane foam part that might degrade and become toxic.

The company has produced 15 million devices using the foam since 2009 but some are not in use.

On Nov. 12, the U.S. Food and Drug Administration (FDA) said that it had obtained new information during inspections of the company's Murraysville, PA facility.

The FDA asked Philips to conduct more tests on the foam used in the recalled ventilators and said the company has not sufficiently demonstrated that other devices containing the foam should not also be recalled. It also said Philips' procedures for design change may not be adequate.

"We will work closely with the FDA to clarify and follow up on the inspectional findings and its recent requests related to comprehensive testing," Philips CEO Frans van Houten said in a statement.

"Until we have concluded these discussions, we are not able to publicly provide further details."

It said it expected to complete its own testing of the foam in the fourth quarter.

The company has been using a replacement silicone-based foam which must now also undergo further safety testing.

The FDA statement said that while it could not be sure, on the basis of what it knows now, that the silicone-based foam being used for repaired products is safe either, it does not recommend patients stop using them, based on a risk-benefit assessment.

Read also: Philips ventilator recall troubles deepen as USFDA finds new issues

Philips has so far put aside 500 million euros ($572.50 million in provisions for recall costs. In October it lowered financial forecasts for the year, citing fallout from the recall and related lawsuits.

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Philips, USFDA in talks post new ventilator findings

Similar News

Sanofi Tzield approved in China for adult, pediatric patients with stage 2 type 1 diabetes

Biocon appoints Rajesh Umakant Shanoy as Company Secretary, Compliance Officer

JnJ bags USFDA nod for bladder cancer treatment Inlexzo

Indian Pharma Market Grows 8.7% in August, Records Rs 20,984 Crore Sales: PharmaTrac

NPPA Clarifies Pharma Data Tender Terms, Technical Presentations on Sept 19

Active Pharm Chemicals Loses Rs 2.17 Crore in API Supply Fraud, 4 Booked

Chemist Body Seeks Transition Period, GST Input Adjustment After Tax Cut, Writes to CM

Strides Pharma Science Singapore arm, Kenox Pharma partner to develop multiple nasal spray products for US